Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › IL-5Rα

IL-5Rα

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
IL-5/IL-5Rα blockade provides clinically validated benefit in EGPA but requires phenotype-specific evidence for other conditions
Neurology Sys. Review
IL-5/IL-5Rα blockade provides clinically validated benefit in EGPA but requires phenotype-specific evidence for other conditions Targeting Eosinophils Shows Promise for Specific Autoimmune Conditions
This narrative review explores the role of eosinophils and IL-5/IL-5Rα and IL-4Rα blockade in various autoimmune diseases. The authors concl…
New research highlights how targeting specific immune cells like eosinophils can help manage certain inflammatory and autoimmune diseases.
Frontiers Oct 20, 2026
Systematic review of anti-IL-5 biologics in hypereosinophilic syndrome kidney disease reports low certainty evidence
Allergy & Immunology Meta-analysis
Systematic review of anti-IL-5 biologics in hypereosinophilic syndrome kidney disease reports low certainty evidence New Clues Help Doctors Spot Kidney Trouble in Rare Blood Disease
This systematic review with narrative synthesis evaluates anti-IL-5 and IL-5Rα biologics in patients with histologically confirmed hypereosi…
A new review shows kidney issues in rare blood disorders are tricky to diagnose but may respond well to specific drugs.
Frontiers Apr 23, 2026